August 7, 2023 02:49 PM EDTUpdated 03:00 PM
Pharma

J&J inks an­oth­er Ste­lara biosim­i­lar set­tle­ment, push­ing Formy­con’s can­di­date in­to po­ten­tial 2025 launch

Paul Schloesser

Associate Editor

An­oth­er biosim­i­lar ver­sion of John­son & John­son’s Ste­lara has been de­layed af­ter the phar­ma gi­ant inked a new agree­ment with two Eu­ro­pean drug­mak­ers de­vel­op­ing a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times